Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Testosterone Undecanoate

FDA-approved product (injectable, intramuscular), marketed as Aveed, Jatenzo, Kyzatrex and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Testosterone Undecanoate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Hypogonadism
  • Hypogonadotropic hypogonadism
  • Klinefelter's syndrome
  • Neoplasm
  • Orchitis
  • Physiological sexual disorder
  • Sexual dysfunction

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
3-oxoandrosten (4) derivatives
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Testosterone Undecanoate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Testosterone Undecanoate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men

    NCT04467697 · start 2018-09-18

    Registered record
    Registry ID
    NCT04467697
    Conditions
    Hypogonadism, Male
    Interventions
    SOV2012-F1
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-09-18
    Completion
    2020-05-01
    Enrolment
    155

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male
    InterventionSOV2012-F1
    PhasePhase 3
    Registry statusCompleted

  • Ambulatory Blood Pressure Monitoring in Oral Testosterone Undecanoate (TU, LPCN 1021) Treated Hypogonadal Men

    NCT03868059 · start 2018-04-30

    Registered record
    Registry ID
    NCT03868059
    Conditions
    Hypogonadism, Male
    Interventions
    LPCN 1021
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-04-30
    Completion
    2019-02-21
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male
    InterventionLPCN 1021
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

    NCT03198728 · start 2017-07-05

    Registered record
    Registry ID
    NCT03198728
    Conditions
    Hypogonadism, Male
    Interventions
    SOV2012-F1; AndroGel
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-07-05
    Completion
    2020-05-01
    Enrolment
    314

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male
    InterventionSOV2012-F1; AndroGel
    PhasePhase 3
    Registry statusCompleted

  • Testosterone Plus Finasteride Treatment After Spinal Cord Injury

    NCT02248701 · start 2017-04-27

    Registered record
    Registry ID
    NCT02248701
    Conditions
    Spinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries; Central Nervous System Diseases; Nervous System Diseases; Spinal Cord Diseases; Gonadal Disorders; Endocrine System Diseases; Hypogonadism; Genital Diseases, Male
    Interventions
    Testosterone Enanthate; Finasteride; Placebo injection; Placebo pill
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2017-04-27
    Completion
    2021-08-13
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Cord Injury; Spinal Cord Injuries; Trauma, Nervous System; Wounds and Injuries +7 more
    InterventionTestosterone Enanthate; Finasteride; Placebo injection; Placebo pill
    PhasePhase 2
    Registry statusTerminated

  • Dosing Flexibility Study of Oral Testosterone Undecanoate (TU, LPCN 1021)

    NCT03242408 · start 2017-01

    Registered record
    Registry ID
    NCT03242408
    Conditions
    Hypogonadism, Male
    Interventions
    LPCN 1021
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2017-01
    Completion
    2017-07
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male
    InterventionLPCN 1021
    PhasePhase 3
    Registry statusCompleted

  • The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate

    NCT02921386 · start 2016-10

    Registered record
    Registry ID
    NCT02921386
    Conditions
    Hypogonadism
    Interventions
    Oral Testosterone Undecanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2016-10
    Completion
    2017-01-21
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionOral Testosterone Undecanoate
    PhasePhase 2
    Registry statusCompleted

  • A Study of Oral Testosterone Undecanoate (TU) in Hypogonadal Men

    NCT02722278 · start 2016-03

    Registered record
    Registry ID
    NCT02722278
    Conditions
    Hypogonadism
    Interventions
    Oral Testosterone Undecanoate; Axiron Testosterone Topical Solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-03
    Completion
    2016-11
    Enrolment
    222

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionOral Testosterone Undecanoate; Axiron Testosterone Topical Solution
    PhasePhase 3
    Registry statusCompleted

  • Testosterone Therapy in Hypogonadal Men Treated With Opioids

    NCT02433730 · start 2015-05-01

    Registered record
    Registry ID
    NCT02433730
    Conditions
    Hypogonadism
    Interventions
    Testosterone; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-05-01
    Completion
    2019-09-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionTestosterone; placebo
    PhasePhase 4
    Registry statusCompleted

  • Testosterone-Dependent Effects on Protein Biomarkers From Healthy Males

    NCT03541395 · start 2015-03

    Registered record
    Registry ID
    NCT03541395
    Conditions
    Hypogonadism, Male
    Interventions
    GnRH antagonist
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-03
    Completion
    2015-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism, Male
    InterventionGnRH antagonist
    PhaseNot applicable
    Registry statusCompleted

  • Testosterone, Metformin, or Both, for Hypogonadism in Obese Males

    NCT02514629 · start 2013-07-04

    Registered record
    Registry ID
    NCT02514629
    Conditions
    Hypogonadism; Obesity
    Interventions
    Placebo; Metformin; Testosterone Undecanoate; Metformin + Testosterone Undecanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-07-04
    Completion
    2016-07-12
    Enrolment
    107

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism; Obesity
    InterventionPlacebo; Metformin; Testosterone Undecanoate; Metformin + Testosterone Undecanoate
    PhasePhase 3
    Registry statusCompleted

  • Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS)

    NCT01919294 · start 2013-07

    Registered record
    Registry ID
    NCT01919294
    Conditions
    Nonalcoholic Steatohepatitis; Hypogonadism
    Interventions
    testosterone undecanoate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-07
    Completion
    2017-01-30
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNonalcoholic Steatohepatitis; Hypogonadism
    Interventiontestosterone undecanoate
    PhasePhase 2
    Registry statusCompleted

  • Oral Testosterone for the Treatment of Hypogonadism

    NCT01717768 · start 2012-10

    Registered record
    Registry ID
    NCT01717768
    Conditions
    Hypogonadism
    Interventions
    TSX-002
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-12
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHypogonadism
    InterventionTSX-002
    PhasePhase 2
    Registry statusCompleted

  • Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men

    NCT01699178 · start 2012-08

    Registered record
    Registry ID
    NCT01699178
    Conditions
    Male Hypogonadism
    Interventions
    Oral testosterone undecanoate; Transdermal testosterone gel (AndroGel)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-08
    Completion
    2014-04
    Enrolment
    182

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMale Hypogonadism
    InterventionOral testosterone undecanoate; Transdermal testosterone gel (AndroGel)
    PhasePhase 3
    Registry statusCompleted

  • Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women

    NCT01724658 · start 2012-06

    Registered record
    Registry ID
    NCT01724658
    Conditions
    Female Sexual Dysfunction
    Interventions
    Testosterone undecanoate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2013-05
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFemale Sexual Dysfunction
    InterventionTestosterone undecanoate; placebo
    PhasePhase 2
    Registry statusCompleted

  • Oral Testosterone for Fatigue in Male Multiple Sclerosis Patients

    NCT01516554 · start 2012-02

    Registered record
    Registry ID
    NCT01516554
    Conditions
    Multiple Sclerosis; Fatigue
    Interventions
    Testosterone undecanoate; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2012-02
    Completion
    2014-07
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Sclerosis; Fatigue
    InterventionTestosterone undecanoate; placebo
    PhasePhase 2
    Registry statusTerminated